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Abstract Structure-dependent μ-opioid receptor (MOR) ac-
tivity is an important element in cancer opioid analgesic effec-
tiveness. It is widely accepted that guanine (G) substitution for
adenine (A) at OPRM1 gene sequence position 118 changes
receptor glycosylation pattern. This is associated with de-
creased binding ability in both exogenous and endogenous
opioids, resulting in increased human pain resistance. The
endogenous opioid system’s function in body homeostasis
maintenance is considered mainly regulatory, so its participa-
tion in breast tumor formation and progression is identified
herein. We examine the association of the most frequent MOR
(A118G) gene polymorphism on breast cancer risk in a North-
eastern Polish population by PCR-RFLP comparison of A and
G allele frequency at OPRM1 gene A118G polymorphic site
in breast cancer-diagnosed patients with healthy control group
frequencies. Our results highlight a strong association be-
tween G allele presence at μ-opioid receptor A118G and
increased breast cancer incidence (OR=3.3, 95 % CI 2.2–
5.0, p<0.0001) and female gender (OR=2.0, 95 % CI 1.4–
2.9, p=0.0004). Consequently, OPRM1 G allele presence at
that site is a highly significant risk factor in breast cancer
development.
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Introduction
The GLOBOCAN2012 International Agency for Research on
Cancer database shows breast cancer (BC) is the most com-
mon cancer in females worldwide, at approximately 25 % of
all female cancers, and the second most commonly occurring
malignancy. It ranks as the fifth major global cause of cancer
death and the second in developed countries [1]. It is currently
believed that tumor development in the majority of cases is
associated with a genetic background, and this includes spo-
radic tumors [2]. This resulted from increased focus on natural
gene population variability as a determinant of cancer suscep-
tibility. At least 80 different genes with 145 variants were
investigated to determine the relationship between single nu-
cleotide polymorphisms (SNPs) and breast cancer risk, with
polymorphism considered significant in approximately 35
genes with 46 variants [3]. Herein, the previously untested
μ-opioid receptor gene (OPRM1) is examined as the newest
candidate in this regard.
Opioids form part of the extensive physiological system of
neuronal, hormonal, and immune regulation essential for
bodily homeostasis maintenance. Their pain perception con-
trol and analgesia is moderated by endogenous and exogenous
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opioid peptide interaction with receptors situated in the central
and peripheral nervous systems, in the immunologic system,
and on the endothelial cell surface [4–7].
While opioid influence on tumor growth and cancer
progression is less established, there is increasing evi-
dence for its support [8–13]. μ-Opioid receptor (MOR)
expression in breast cancer cells has been demonstrated
in both the MCF-7 and T47D ER-positive BC cell lines
and in patient biopsy specimens [14–17]. Chatikhine
and coworker’s immunohistochemical studies [18]
showed that the most common type of BC invasive
ductal carcinomas can prove positive for β-endorphin
and Met-enkephalin opioid peptides [18]. Further re-
search has revealed that clinically relevant doses of an-
algesic opioids, such as morphine, promote basal cell
proliferation and migration, and accompanying angio-
genesis results in direct tumor growth and metastasis
[9, 19, 20] or in indirect morphine-induced immunosup-
pression [13]. In contradistinction, however, morphine
and other opioids also promote tumor cell death [15,
16, 21]. While these facts suggest that the endogenous
opioid system can participate in breast cancer develop-
ment and progression, many results on opioid and BC
interrelationships are contradictory. One reason for this
discord may be genetic variation in the OPRM1 gene.
The human OPRM1 gene is located on chromosome
6q24–q25. It spans 236 kb with at least 11 exons and
17 different splice variants under the control of multiple
promoters [22]. The most commonly occurring MOR
polymorphism is A118G variant (rs1799971). This is
located in the first exon of gene and consists of non-
synonymous substitution of guanine (G) for adenine
(A), resulting in the exchange of aspartic acid for aspar-
agine at MOR protein position 40 (N40D). This leads to
loss of the N-glycosylation site in the G protein-coupled
receptor’s extracellular region and associated change in
its molecular level function [23]. Clinical observations
have demonstrated a relationship between A118G poly-
morphism frequency and response to exogenous opioids,
with resultant pain threshold variation [24–28]. Further
studies suggest that G allele carriers exhibit decreased
breast cancer-specific mortality [29] and significantly
lowered risk of esophageal carcinoma development [30].
Our previous research identified opioid peptides in
lactating women’s milk, where concentrations of
cryptopeptides derived from human β-casein β-
casomorphin-5 and β-casomorphin-7 were dependent
on lactation phase [31]. This result combined with lac-
tation as a protective factor in breast cancer risk and the
abovementioned opioid participation in tumor biology
prompted our examination of the relationship between
the A118G polymorphism in the OPRM1 μ-opioid re-
ceptor gene and breast cancer occurrence.
Patients and methods
Patients and control group characteristics
Our study subjects were 151 recently diagnosed female breast
cancer patients recruited at the Department of General Surgery
and Oncology of the Warmia and Mazury University Hospital
and at the General and Oncologic Surgery Wards of the
Warmia and Mazury Oncology Centre in Olsztyn in 2013–
2014. The contraindications for research qualification were
breast cancer recurrence after previous surgery, metastasized
cancer from other organs, and/or previous radiotherapy or
chemotherapy. The control group consisted of 590 unrelated
volunteers recruited on the basis of the screening at the
abovementioned departments and at the University Health
Center in Olsztyn who had not reported of any type of cancer,
infectious disease, or surgery for at least 3 years prior to re-
cruitment. Both experimental and control group members re-
ported a history of no opioid drug use. All participants gave
informed consent and data was collected from their medical
records and/or a completed questionnaire. Each person sup-
plied peripheral blood as research material, and all investiga-
tion procedures accorded with ethical standards and were ap-
proved by the Local Bioethics Committee (permit number:
OIL.492/12/Bioet).
Sample genotyping
Participant’s 2-mL peripheral venous blood samples were col-
lected in Vacutainer EDTA tubes, marked with individual ID
code, and transported to the laboratory in blind case-control
status. Genomic DNA was isolated from whole blood using
GeneJET™ Whole Blood Genomic DNA Purification Mini
Kit (Thermo Scientific) according to the manufacturer’s in-
structions and stored at −80 °C prior to genotyping. The se-
lection of the OPRM1 PCR reaction primers was based on
Romberg et al.’s publication [32], with the following se-
quences: Oprm1F-5′-GGTCAACTTGTCCCACTTAGAT
CGC-3′ and Oprm1R-5 ′-AATCACATACATGACCA
GGAAGTTT-3′.
PCR amplification was conducted in a thermal cycler ac-
cording to the following conditions: initial denaturation at
94 °C for 3 min, followed by 40 cycles of 30 s at 94 °C
complete denaturation, 30 s at 61 °C for starter attachments,
30 s synthesis at 72 °C, and final elongation at 72 °C for 5 min.
The 25-μL mixture volume comprised DreamTaq™ Green
Master Mix (Thermo Scientific), specific starters, the DNA
matrix, and molecularly pure water (Sigma-Aldrich). The
PCR product yield and specificity were evaluated by electro-
phoresis in 1.5 % agarose gel (Promega) stained with
GelGreen (Biotium). The PCR products were then digested
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with FastDigest® Bsh1236I restriction enzyme (Thermo Sci-
entific) according to the manufacturer’s instructions, separated
on 2.5 % agarose gel, and identified by GelGreen (Biotium)
staining. Genotyping was confirmed by the DNA sequencing
of random chosen samples.
Statistical analysis
The frequency distribution of common risk factors for BC,
including age, menstrual and menopausal history, age at men-
arche and at first child birth, breast-feeding, family history of
BC, and smoking, was examined in our study population by
the Pearson χ2 test or by the Mann–Whitney U test. The
genotype distribution among subjects was analyzed for Har-
dy–Weinberg equilibrium (HWE) using the chi-square test,
and genotype and SNP allele frequencies were compared in
cancer patients and control groups by Fisher’s test. Odds ratios
(ORs) and 95 % confidence intervals (CIs) were calculated
using logistic regression analysis and used to compare both
allele frequencies in cancer patients and healthy controls, and
allele frequencies between female and male. The risk of breast
cancer development was estimated via variant GG and AG
genotype comparison with the wild-type AA homozygote.
Statistical analysis was conducted on GraphPad Prism soft-
ware (v 6.01; San Diego, CA, USA), with a p value ≤0.05
considered statistically significant.
Results
The study population consisted of 151 histopathologically
confirmed breast cancer patients and 590 healthy controls
(287 female and 303 male). The distribution of selected char-
acteristics in breast cancer females and healthy volunteers is
listed in Table 1, with no statistically significant differences in
the majority of compared features. All subjects were Cauca-
sians, of approximately the same age. Both healthy and breast
cancer female groups (HF and BCF, respectively) had similar
fertility rates, and they reached sexual maturity, menopausal
status, and gave birth at equivalent ages. Most HF and BCF
were breast-fed, with a slightly less percent in the BCF group.
While 10 % of both groups were nulliparous, more BC fe-
males were postmenopausal (p=0.03) and more were smokers
(p=0.03). In addition, while both female groups, and only a
fewmore BC than HF, reported a positive breast cancer family
history, healthy males recorded BC occurrence in their female
relatives twice less frequently (p=0.02). Clinical evidence and
histopathology classified all BCs herein invasive, with 58 %
in stage I and 42 % in stage II (data not shown).
The observed genotype distribution of OPRM1 A118G
polymorphism in both control subgroups and cancer patients
conformed to the Hardy–Weinberg equilibrium (p>0.05).
This suggests no population stratification and no sampling
bias. The AA, AG, and GG genotypes were identified, with
0.1 G allele frequency in the entire research population. Of the
total 741 participants, 609 had genotypeAA, 119 had AG, and
13 had GG. These latter 13 GG genotypes were in 5 healthy
individuals and 8 cancer-diagnosed patients. All healthy GG
homozygous carriers were females under 50 years of age, and
3 of these were premenopausal. The AG genotype was present
in 75 healthy control individuals and 44 BC patients. The
respective genotype distribution and A/G allele frequencies
are listed in Table 2.
Our results suggest a strong association between the pres-
ence of the G allele at position 118 of the μ-opioid receptor
gene and increased breast cancer incidence (OR=3.3, 95% CI
2.2–5.0, p<0.0001). Significant difference was also identified
in G allele occurrence in the female gender (OR=2.0, 95% CI
1.4–2.9, p=0.0004).
Discussion
Although the endogenous opioid system’s precise role in tu-
mor initiation and development remains undetermined, a rela-
tionship with cancer is anticipated because it plays a regula-
tory function in organism homeostasis, and opioid peptides
and receptors are present in cancer cells [14, 17, 18]. The
identification of functionally significant genetic variation in
the opioid system compounds this issue. Global reports indi-
cate that OPRM1 A118G allele frequencies are highly depen-
dent on ethnicity, where the overall G allelic frequency varies
between 0.8 and 48 % in different ethnic groups [23]. Geno-
typic distribution analysis of our entire population identified
10 % G allele frequency, thus approximating the established
global Caucasian frequency of 11–17 % [23].
Herein, we investigated the association between A118G
OPRM1 gene polymorphism and breast cancer risk. We found
that female G allele carriers had more than three times in-
creased breast cancer risk than both healthy female and the
entire control group. The one previous study on the relation-
ship between A118G OPRM1 gene and breast cancer by
Bortsov et al. recorded that breast cancer-specific mortality
was significantly reduced in patients possessing the OPRM1
118G variant allele [29]. Additionally, while the protective
effect of this SNP was limited only to invasive cases, it in-
creased with increasing cancer diagnosis stage. These authors
concluded this was due to reduced opioid response in patients
who possessed one or both G alleles. In contrast, we examined
only primary invasive breast cancer patients with no history of
opioid use. The μ-opioid G variant receptor may therefore
play a protective role by decreasing opioid drug action in
cancer progression and metastasis, and simultaneously in-
crease the risk of endogenous opioid peptide action in the
carcinogenic process. Mura et al.’s [23] summary of research
into the molecular consequences of A118GOPRM1 polymor-
phism indicates that this phenomenon is possible because, in
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contrast to the wild-type A variant N40 receptor effect, the G
variant receptor can be associated with both decreased and
increased signal transduction. It is important to note here that
females can also be influenced by β-casomorphin-5 and β-
casomorphin-7 opioid peptides in lactation milk. While both
β-casomorphin peptide concentrations changed with lactation
phase in healthy breast-feeding females [31], concentrations
remained the same throughout lactation in the breast milk of
females with food allergies [33]. While this expected time-
dependent β-casomorphin gradient in healthy lactating fe-
males inspires a comparative study of the interrelationships
between breast-feeding period, respective genotypes, and
breast cancer diagnosis, our current study group has inappro-
priate stratification to pursue this herein. Future research will
establish study population stratification which identifies inter-
relationships between the number of live births, maternal lac-
tation duration, feeding periods, and food allergy status.
Mainstream clinical A118G OPRM1 polymorphism anal-
ysis focuses on opioid-induced analgesia and opioids, vulner-
ability to alcohol and nicotine addiction, and therapy re-
sponse. It is interesting here that our female OPRM1 G allele
frequency is approximately twice that of males. No males
were GG homozygous and only 40 carried one G allele. Some
studies indicate gender-specific associations [34–36], and
Fillingim et al.’s allelic distribution of tested SNP in healthy
people specifies only females [28]. Although these authors’
population was more ethnically diverse than ours, their G
allele overrepresentation in females is consistent with our re-
sults. This may constitute one explanation why breast cancer
is so rare in males; accounting for only 0.6 % of all breast
cancer patients worldwide [37]. It is acknowledged that male
BC does not significantly differ from female BC, except in
obvious gender-specific differences, and also that breast can-
cer is more likely to be estrogen receptor (ER)-positive in
Table 2 Genotype and allele
frequencies of OPRM1 gene
A118G polymorphism in studied
groups and G allele breast cancer
association
CI confidence interval, OR odds
ratio
a OR adjusted for age, age of
menarche and menopause, age of
first birth, number of live births,
breast-feeding, postmenopausal
status, family history of cancer,
and smoking status
b OR adjusted for age, family
history of cancer, and smoking
status
Research group % of genotypes Frequency of alleles
AA AG GG A G
Study population (n=741) 82.2 16.1 1.7 0.90 0.10
Control group M+F (n=590) 86.4 12.7 0.9 0.93 0.07
Healthy male (n=303) 86.8 13.2 0.0 0.91 0.09
Studied female (BC+H) (n=438) 79.0 18.0 3.0 0.88 0.12
Healthy female (n=287) 86.1 12.8 1.7 0.92 0.08
Breast cancer female (n=151) 65.6 29.1 5.3 0.80 0.20
OR (95 % CI)
GG+AG vs AA
p value
Breast cancer female vs. healthy female 3.3 (2.2–5.0)a <0.0001
Breast cancer female vs. control group M+F 3.6 (2.5–5.2)b <0.0001
Female (BC+H) vs. male 2.0 (1.4–2.9)b 0.0004
Healthy female vs. healthy male 1.2 (0.8–1.9)b 0.42
Table 1 Distribution of selected
characteristics in breast cancer
patients and healthy individuals
n.a. not applicable
a Two-sided Pearson χ2 test and
Mann–Whitney test where it is
appropriate.
b Among 135 parous BC cases
and 259 parous controls
c Among 143 parous BC cases















Age (years), mean (SD) 49.8 (12.4) 53.3 (26.2) 55.1 (10.3) 0.93/0.28
Age of menarche (years), mean (SD) n.a. 13.3 (1.1) 13.1 (1.2) 0.35
Age of first birth (years)b, mean (SD) n.a. 26.1 (3.5) 25.8 (3.5) 0.35
Number of live birthsb, mean (SD) n.a. 1.8 (0.6) 2.0 (0.7) 0.62
Age at menopause (years)c, mean (SD) n.a. 48.3 (2.4) 49.1 (3.1) 0.27
Postmenopausal status, % n.a. 88.2 94.7 0.03
Breast-feedingb, % n.a. 80.1 74.9 0.13
Nulliparous, % n.a. 9.8 10.6 0.78
Positive family history of BC, % 8.5 13.6 17.3 0.31/0.02
Smoking, % 34.8 28.3 37.0 0.03/0.72
Ethnicity (Caucasian race), % 100 100 100 1.00/1.00
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males than in females [38]. It should be noted that functional
relationship between ERα andMOR has been reported recent-
ly. It was shown that MOR activation leads to ERα activation
and mediates its translocation to the plasma membranes. The
synergistic induction of breast cancer cell proliferation has
been observed as the final effect [39]. Moreover, it has also
been shown that expression of ERβ can be regulated by opi-
oids [40]. In conclusion, since theMORG allele (40D variant)
proves more sensitive to endogenous opioid peptides and pro-
motes the recently reported estrogen receptor interaction, our
results highlight the significance of the OPRM1 G allele as a
serious risk factor in breast cancer development.
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